Xie Xiaoliang: The medium antibody is expected to become a special drug for new coronary pneumonia, which can be treated and prevented in the short term.

On August 8th, at the New Crown Therapeutic Antibody and Vaccine Forum of the HCare Global Health Industry Summit, Xie Xiaoliang, Director of the Center for Biomedical Frontier Innovation at Peking University and Director of the Beijing Future Gene Diagnostics High-Tech Innovation Center and a foreign academician of the Chinese Academy of Sciences, said that so far, we do not have a small molecular special drug for the new coronary virus, and neutralized antibodies are expected to become special effects for the new coronary pneumonia.
Xie Xiaoliang said, neutral antibodies have a double-edged effect, can be used as both therapeutic drugs, but also as short-term preventive drugs.
the treatment of new coronary pneumonia is in urgent need of strong drugs, plasma therapy, although the effect is remarkable, but due to limited plasma sources, can not be widely used.
and the antibody is produced by the body's immune system and is a key component of plasma therapy.
"the acid is coming, we're using alkalis to make up;
", therefore, Xie Xiaoliang's team's goal is to quickly find and prepare high-strength, medium antibodies for injection as a drug instead of plasma.
Xie Xiaoliang said that the new coronary pneumonia drug should meet the following criteria, that is, significantly reduce the proportion of patients with mild to medium to severe illness, significantly reduce the damage to the lungs and other tissues of patients, and quickly cure patients with mild illness to shorten hospital stay. using new single-cell genomics techniques,
's team of scientists sifted through more than 400 of the most intensive IgG antibody sequences from 8,558 antibody sequences in the plasma of more than 60 patients recovering from new coronary pneumonia, from which they found more than 20 highly active and moderate antibodies.
, the antibody number BD368-2 is outstanding and has significant therapeutic effect.
Xie Xiaoliang's team used single-cell genomics to screen out highly active and antibody new crown viruses using their surface protrusion protein (S protein) as the virus 'key' to "unlock" and invade human cells, and the binding of the S protein receptor binding region (receptor-binding domain, RBD) to the ACE2 receptor on the cell surface is the first step in its invasion of cells.
the structure of the frozen electroscope showed that well-iclerotic and active antibodies were able to bind to the binding domain (RBD) on the new crown virus S protein, which in turn prevented them from invading human cells.
notably, the BD368-2-2-medium antibody found by Xie Xiaoliang's team was able to bind to all three RBDs of the S protein, regardless of whether the structure of the RBD was open or closed.
team also found two medium antibodies that did not match at all on the surface, paired with each other to inhibit immune escape.
Using a model of hACE2 genetically modified mice from Professor Qin Chuan's team at the Institute of Medical Experimental Animals of the Chinese Academy of Medical Sciences, Xie Xiaoliang's team found that treating mice with BD-368-2 after contracting the new coronary virus could reduce the viral load by about 2,400 times.
found that BD368-2 antibodies were injected into mice one day before infection compared to the control group, and no viral load was detected in mouse lung tissue five days later.
if BD368-2 antibodies were given 2 hours after infection in mice, the load of lung virus dropped significantly in mice after 5 days, while the weight of mice remained basically the same.
recently, Xie Xiaoliang's team has conducted more animal experiments.
in hamster experiments, the researchers found that the same dose (20 mg/kg) of the medium antibody was given, even after the transfer window was moved to the virus 48 hours after the inoculation, the medium antibody was still effective.
Because hamsters metabolize much faster than humans, they correspond to humans, suggesting that the medium antibody is still effective 7 to 10 days after a person becomes infected with a new crown, i.e. when the disease develops into a mid-stage disease.
it is understood that for the drug production and trial of the medium antibody, due to the reduction in the number of domestic patients, the relevant clinical trials will be conducted in Beijing Danse Pharmaceutical Co. , Ltd. under the coordination of Australia and other countries.
The results of Xie Xiaoliang's team's work on neutralizing antibodies that are expected to be powerful drugs for the treatment of new coronary pneumonia were published online in cell magazine, entitled "Potent neutralizing antibodies against SARS-CoV-2 identified by high-high-gonc single-cells of the convalescents' B cells".
()